Q2 2026 West Pharmaceutical Services Inc Earnings Call Transcript
Key Points
- West Pharmaceutical Services Inc (WST) reported strong second quarter results with revenues of $872 million, up 13% organically, and adjusted EPS of $2.37, up 29% compared to the prior year.
- The company raised its full-year 2026 guidance, anticipating organic revenue growth of 10% to 11% and adjusted EPS in the range of $8.85 to $9.05.
- The Proprietary Products segment delivered 16% organic growth, driven by the Biologics market group, which was up 29% organically.
- HVP components, which now account for 49% of total company revenues, saw an 18% organic increase, driven by biologics, biosimilars, and GLP-1 elastomers.
- The company reported double-digit growth across all three geographies, with Asia Pacific leading at 27% organic growth, highlighting the global breadth of its business.
- The West Vantage segment grew only 0.8% organically, slightly below expectations due to the impact of a cyber incident.
- The cyber incident in early May had a mid-single-digit impact on growth, pushing some revenues into the second half of the year.
- Despite strong performance, the company remains cautious with its forecasting, indicating a conservative outlook for the second half of the year.
- Inflationary pressures from higher oil and commodity prices are being managed, but they remain a concern for margin performance.
- The divestiture of the SmartDose 3.5 ml on-body delivery system is expected to impact reported growth figures in the second half of the year.
Good day and welcome to the West Pharmaceutical Services Q2 2026 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker, Mr. John Sweeney, Vice President of Investor Relations. Please go ahead, sir.
Good morning, and welcome to West's second quarter 2026 earnings conference call, which is being webcast live today. With me on the call are Eric Green, our CEO, Chair of the Board; and Bob McMahon, CFO.
Earlier today, we issued our second quarter financial results A copy of the press release, along with today's slide presentation containing supplemental information for your reference has been posted in the Investors section of the company's website at investor.westpharma.com.
Later today, a replay of the webcast will also be available in the Investors section of our website. Before we begin, we'd like to remind you that statements made by
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
